Skip to content

68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinoma

68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinoma - PSMA-PET imaging for advanced ACC/SDC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON44299
Enrollment
25
Registered
2017-08-30
Start date
2017-11-13
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoid cystic carcinoma salivary duct carcinoma salivary gland cancer

Interventions

Study procedure 1. Before screening visit: - Eligible patients will be informed about the study during normal patient care. If the patient is considering to participate, a screening visit will be p
adenoid cystic carcinoma
Positron-Emission Tomography
salivary duct carcinoma

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - locally advanced, recurrent or metastatic ACC or SDC - Age * 18 years old - Ability to provide written informed consent

Exclusion criteria

Exclusion criteria: - Contra-indication for PET imaging: pregnancy, breast feeding, severe claustrophobia - Impaired renal function: MDRD

Design outcomes

Primary

MeasureTime frame
Primary objective - To evaluate the uptake of 68Ga-PSMA in locally advanced, recurrent and metastatic ACC or SDC by performing 68Ga-PSMA-PET/CT scans.

Secondary

MeasureTime frame
Secondary objectives - To calculate the SUV tumor-to-background ratio and tumor-to-*healthy salivary gland tissue* ratio. - Correlate the tumor uptake (SUV) to the degree of immunohistochemical PSMA expression of the primary tumor on archival tissue or a fresh biopsy. - To establish whether new metastatic lesions are found by 68GA-PSMA-PET/CT imaging.

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)